File Download
  Links for fulltext
     (May Require Subscription)

Article: A pilot study of low-dose erythromycin in bronchiectasis

TitleA pilot study of low-dose erythromycin in bronchiectasis
Authors
KeywordsBronchiectasis
Cilia
Cytokines
Erythromycin
Sputum
Issue Date1999
PublisherEuropean Respiratory Society. The Journal's web site is located at http://erj.ersjournals.com
Citation
European Respiratory Journal, 1999, v. 13 n. 2, p. 361-364 How to Cite?
AbstractPatients with bronchiectasis suffer from sputum production, recurrent exacerbations, and progressive airway destruction. Erythromycin is effective in diffuse panbronchiolitis, another suppurative airway disorder, although its efficacy is unknown in idiopathic bronchiectasis. A double-blind placebo- controlled study was therefore conducted to evaluate the effects of 8-week administration of low dose erythromycin (500 mg b.i.d.) in steady-state idiopathic bronchiectasis. Patients in the erythromycin group (n=11, 8 female, mean age 50±15 yrs), but not the placebo group (n=10, 8 female, mean age 59±16 yrs) had significantly improved forced expiratory volume in one second, forced vital capacity and 24-h sputum volume after 8 weeks (p<0.05). There was no parallel improvement in sputum pathogens, leukocytes, interleukin (IL)-1α and IL-8, tumour necrosis factor-α, or leukotriene B4. The results of this pilot study show that low-dose erythromycin improves lung function and sputum volume in bronchiectasis. Further studies are indicated to evaluate the efficacy of long-term erythromycin therapy in bronchiectasis.
Persistent Identifierhttp://hdl.handle.net/10722/49023
ISSN
2015 Impact Factor: 8.332
2015 SCImago Journal Rankings: 3.204
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTsang, KWTen_HK
dc.contributor.authorHo, PLen_HK
dc.contributor.authorChan, KNen_HK
dc.contributor.authorIp, MSMen_HK
dc.contributor.authorLam, WKen_HK
dc.contributor.authorHo, CSen_HK
dc.contributor.authorYuen, KYen_HK
dc.contributor.authorOoi, GCen_HK
dc.contributor.authorAmitani, Ren_HK
dc.contributor.authorTanaka, Een_HK
dc.date.accessioned2008-06-12T06:32:29Z-
dc.date.available2008-06-12T06:32:29Z-
dc.date.issued1999en_HK
dc.identifier.citationEuropean Respiratory Journal, 1999, v. 13 n. 2, p. 361-364en_HK
dc.identifier.issn0903-1936en_HK
dc.identifier.urihttp://hdl.handle.net/10722/49023-
dc.description.abstractPatients with bronchiectasis suffer from sputum production, recurrent exacerbations, and progressive airway destruction. Erythromycin is effective in diffuse panbronchiolitis, another suppurative airway disorder, although its efficacy is unknown in idiopathic bronchiectasis. A double-blind placebo- controlled study was therefore conducted to evaluate the effects of 8-week administration of low dose erythromycin (500 mg b.i.d.) in steady-state idiopathic bronchiectasis. Patients in the erythromycin group (n=11, 8 female, mean age 50±15 yrs), but not the placebo group (n=10, 8 female, mean age 59±16 yrs) had significantly improved forced expiratory volume in one second, forced vital capacity and 24-h sputum volume after 8 weeks (p<0.05). There was no parallel improvement in sputum pathogens, leukocytes, interleukin (IL)-1α and IL-8, tumour necrosis factor-α, or leukotriene B4. The results of this pilot study show that low-dose erythromycin improves lung function and sputum volume in bronchiectasis. Further studies are indicated to evaluate the efficacy of long-term erythromycin therapy in bronchiectasis.en_HK
dc.format.extent420 bytes-
dc.format.mimetypetext/html-
dc.languageengen_HK
dc.publisherEuropean Respiratory Society. The Journal's web site is located at http://erj.ersjournals.comen_HK
dc.relation.ispartofEuropean Respiratory Journalen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectBronchiectasisen_HK
dc.subjectCiliaen_HK
dc.subjectCytokinesen_HK
dc.subjectErythromycinen_HK
dc.subjectSputumen_HK
dc.titleA pilot study of low-dose erythromycin in bronchiectasisen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0903-1936&volume=13&issue=2&spage=361&epage=364&date=1999&atitle=A+pilot+study+of+low-dose+erythromycin+in+bronchiectasisen_HK
dc.identifier.emailHo, PL:plho@hkucc.hku.hken_HK
dc.identifier.emailIp, MSM:msmip@hku.hken_HK
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_HK
dc.identifier.authorityHo, PI=rp00406en_HK
dc.identifier.authorityIp, MSM=rp00347en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1183/09031936.99.13236199en_HK
dc.identifier.pmid10065682-
dc.identifier.scopuseid_2-s2.0-0032979242en_HK
dc.identifier.hkuros39782-
dc.identifier.hkuros53643-
dc.identifier.hkuros46384-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032979242&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume13en_HK
dc.identifier.issue2en_HK
dc.identifier.spage361en_HK
dc.identifier.epage364en_HK
dc.identifier.isiWOS:000078776000024-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridTsang, KWT=7201555024en_HK
dc.identifier.scopusauthoridHo, PL=7402211363en_HK
dc.identifier.scopusauthoridChan, KN=15737866400en_HK
dc.identifier.scopusauthoridIp, MSM=7102423259en_HK
dc.identifier.scopusauthoridLam, WK=7203021937en_HK
dc.identifier.scopusauthoridHo, CS=36985962300en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK
dc.identifier.scopusauthoridOoi, GC=7006176119en_HK
dc.identifier.scopusauthoridAmitani, R=7006768416en_HK
dc.identifier.scopusauthoridTanaka, E=7401815855en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats